Entero Therapeutics, Inc. (ENTO)
Q4-CY2025Q3-CY2025Q2-CY2025Q1-CY2025Q4-CY2024Q3-CY2024Q2-CY2024Q1-CY2024Q4-CY2023Q3-CY2023Q2-CY2023Q1-CY2023Q4-CY2022Q3-CY2022Q2-CY2022Q1-CY2022Q4-CY2021Q3-CY2021Q2-CY2021Q1-CY2021Q4-CY2020Q3-CY2020Q2-CY2020Q1-CY2020Q4-CY2019Q3-CY2019Q2-CY2019Q1-CY2019Q4-CY2018Q3-CY2018Q2-CY2018Q1-CY2018Q4-CY2017Q3-CY2017Q2-CY2017Q1-CY2017Q4-CY2016Q3-CY2016Q2-CY2016Q1-CY2016Q4-CY2015Q3-CY2015Q2-CY2015Q1-CY2015Q4-CY2014Q3-CY2014Q2-CY2014Q1-CY2014Q4-CY2013
Balance Sheet Date2025-Sep-302025-Jun-302025-Mar-312024-Dec-312024-Sep-302024-Jun-302024-Mar-312023-Dec-312023-Sep-302023-Jun-302023-Mar-312022-Dec-312022-Sep-302022-Jun-302022-Mar-312021-Dec-312021-Sep-302021-Jun-302021-Mar-312020-Dec-312020-Sep-302020-Jun-302020-Mar-312019-Dec-312019-Sep-302019-Jun-302019-Mar-312018-Dec-312018-Sep-302018-Jun-302018-Mar-312017-Dec-312017-Sep-302017-Jun-302017-Mar-312016-Dec-312016-Sep-30
Fiscal PeriodQ3-FY2025Q2-FY2025Q1-FY2025Q4-FY2024Q3-FY2024Q2-FY2024Q1-FY2024Q4-FY2023Q3-FY2023Q2-FY2023Q1-FY2023Q4-FY2022Q3-FY2022Q2-FY2022Q1-FY2022Q4-FY2021Q3-FY2021Q2-FY2021Q1-FY2021Q4-FY2020Q3-FY2020Q2-FY2020Q1-FY2020Q4-FY2019Q3-FY2019Q2-FY2019Q1-FY2019Q4-FY2018Q3-FY2018Q2-FY2018Q1-FY2018Q4-FY2017Q3-FY2017Q2-FY2017Q1-FY2017Q4-FY2016Q3-FY2016
Operating Cash Flow(855,688$)(54,878$)(818,635$)(171,518$)(1,848,489$)(3,450,860$)(3,746,956$)(3,439,378$)(3,331,212$)(2,761,684$)(2,845,578$)(5,592,289$)(4,254,109$)(4,585,607$)(7,912,074$)(5,862,786$)(15,729,304$)(5,622,734$)(5,073,394$)(5,889,981$)(2,696,824$)(1,343,453$)(1,291,280$)(3,225,985$)(4,153,740$)(4,025,980$)(2,627,797$)(3,340,684$)(2,666,315$)(2,648,054$)(2,214,267$)(2,469,134$)(1,293,064$)(2,257,010$)(1,165,430$)(2,016,909$)(655,361$)(636,546$)(717,156$)
Investing Cash Flow0$0$0$88,169$(10,248,040$)2,480$(73,928$)0$90,158$0$1,532$(4,340$)(6,855$)(3,906$)15$(13,352$)(257,114$)(7,318$)(11,520$)(29,521$)(215$)(10,710$)(20,658$)(585$)785$(10,693$)(936$)(4,484$)
Purchases of Property and Equipment(1,960$)1,359$
Financing Cash Flow3,025,000$0$700,000$(31,798$)1,552,802$681,420$3,378,930$4,358,822$5,387,487$1,933,304$3,547,108$5,524,239$4,771,770$76,375$5,367,147$17,072,855$14,858,038$1,781,977$11,050,623$552,395$13,060,131$677,341$2,756,254$1,846,405$4,403,346$4,928,086$1,967,142$255,032$(313,242$)9,524,637$2,245,701$159,180$337,990$5,593,380$(77,332$)3,652,294$1,869,000$225,000$(308,171$)
End Cash Position2,517,218$4,474$59,352$163,476$366,788$662,479$3,431,913$3,711,770$3,292,327$1,236,054$2,064,435$1,362,910$1,657,013$1,155,009$5,694,988$8,248,684$7,210,645$8,074,491$12,025,632$6,062,141$11,368,680$984,950$1,630,007$175,796$1,549,825$1,310,687$413,858$1,114,343$4,427,640$7,420,425$574,474$573,471$0$0$
Exchange Rate Effect(226,045$)5,848$(30,747$)(8,769$)76,010$4,940$(36,456$)(13,738$)
Dividends Paid
Unlevered Free Cash Flow(855,688$)(54,878$)(818,635$)(171,518$)(1,848,489$)(3,450,860$)(3,746,956$)(3,439,378$)(3,331,212$)(2,761,684$)(2,845,578$)(5,592,289$)(4,254,109$)(4,585,607$)(7,912,074$)(5,860,826$)(15,729,304$)(5,622,734$)(5,073,394$)(5,891,340$)(2,696,824$)(1,343,453$)(1,291,280$)(3,225,985$)(4,153,740$)(4,025,980$)(2,627,797$)(3,340,684$)(2,666,315$)(2,648,054$)(2,214,267$)(2,469,134$)(1,293,064$)(2,257,010$)(1,165,430$)(2,016,909$)(655,361$)(636,546$)(717,156$)